Literature DB >> 9097397

Intermittent morphine administration induces a long-lasting synergistic effect of corticosterone on dopamine D1 receptor functioning in rat striatal GABA neurons.

A N Schoffelmeer1, T J De Vries, L J Vanderschuren, G H Tjon, P Nestby, G Wardeh, A H Mulder.   

Abstract

Glucocorticoid receptor (GR)-mediated facilitation of striatal dopaminergic (DA) neurotransmission has been proposed to play a role in behavioral sensitization induced by intermittent exposure to drugs of abuse or stressors. Searching for possible common neuronal substrates acted upon by drugs of abuse and corticosterone, we addressed the question as to whether such a facilitatory effect is apparent (i.e., persists) in primary cultures of rat striatum subsequent to intermittent (prenatal) morphine administration. As previously observed in striatal slices of morphine-treated rats, intermittent morphine exposure in vivo caused a long-lasting increase in DA D1 receptor-stimulated adenylyl cyclase activity, that appeared to persist in primary cultures of rat striatal gamma-aminobutyric acid (GABA) neurons. Subsequent in vitro exposure of these striatal neurons to corticosterone or dexamethasone, simultaneously activating GR and mineralocorticoid receptors (MR), about doubled this adaptive effect of previous in vivo morphine administration. The selective MR agonist aldosterone was ineffective in this respect. Prior in vivo morphine treatment also enhanced the stimulatory in vitro effect of corticotropin releasing hormone (CRH) on adenylyl cyclase in cultured GABA neurons. However, the enhanced CRH receptor functioning was not potentiated by in vitro corticosterone exposure. Activation of GR by corticosterone did not facilitate the increase in D1 receptor efficacy induced by sustained activation of muscarinic receptors in cultured striatal neurons. These data indicate that previous intermittent morphine administration induces a long-lasting synergistic effect of corticosterone on enhanced striatal DA neurotransmission at the level of postsynaptic D1 receptors. Moreover, the induction of this neuroadaptation seems to display opioid receptor selectivity and its long-term expression may be confined to D1 receptors. Since exposure to drugs of abuse or stressors not only increase striatal DA release but also plasma corticosterone levels, we hypothesize that this adaptive phenomenon in DA-sensitive GABA neurons is involved in the expression of morphine-induced long-term behavioral sensitization to drugs of abuse and stressors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097397     DOI: 10.1002/(SICI)1098-2396(199704)25:4<381::AID-SYN9>3.0.CO;2-6

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  4 in total

1.  Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.

Authors:  A N Schoffelmeer; L J Vanderschuren; T J De Vries; F Hogenboom; G Wardeh; A H Mulder
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine, and neurochemical sensitization in rats.

Authors:  L J Vanderschuren; E D Schmidt; T J De Vries; C A Van Moorsel; F J Tilders; A N Schoffelmeer
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

Review 3.  Activators of G-protein signaling 3: a drug addiction molecular gateway.

Authors:  Michael Scott Bowers
Journal:  Behav Pharmacol       Date:  2010-09       Impact factor: 2.293

4.  Autoantibodies reactive to adrenocorticotropic hormone can alter cortisol secretion in both aggressive and nonaggressive humans.

Authors:  Henning Værøy; Csaba Adori; Romain Legrand; Nicolas Lucas; Jonathan Breton; Caroline Cottard; Jean-Claude do Rego; Céline Duparc; Estelle Louiset; Hervé Lefebvre; Pierre Déchelotte; Elin Western; Stein Andersson; Tomas Hökfelt; Sergueï O Fetissov
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.